When it comes to the world of hair loss, it’s no question that the amount of information out there can feel extremely ...

Adding narrowband ultraviolet B (UVB) phototherapy to oral treatment with ritlecitinib (Litfulo) enhanced repigmentation in ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

The European Commission (EC) has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg ...

Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. A ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...